Abstract:Abstract Objective To explore the relationship between FABP4 and FABP6 expression and the pathogenesis of colorectal cancer (CRC) and their potential as biomarkers in the diagnosis of CRC. Methods In total, 100 CRC patients and 100 controls were enrolled. The serum levels of FABP4 and FABP6 were detected by enzyme-linked immunosorbent assay (ELISA) before and 2 weeks after radical resection of CRC. The protein expressions of FABP4 and FABP6 were observed in colorectal tumor tissues and adjacent tissues by immunohistochemistry and western blot, respectively. The diagnostic performance of FABP4 and FABP6 in patients with CRC was evaluated by receiver operating characteristic (ROC) curve analysis. Results The serum levels of FABP4 and FABP6 in patients with CRC were higher than the levels in the controls before surgery (P < 0.001), and significantly decreased at 2 weeks after operation (P < 0.001). Immunohistochemistry showed that FABP4 and FABP6 were mainly distributed in the cytoplasm of human colorectal tumor tissues, and only a small amount distributed in adjacent tissues. Western blot revealed that the protein expressions of FABP4 and FABP6 were significantly higher in tumor tissues than in adjacent tissues (P < 0.001, P = 0.002, respectively). Tumors with high and low FABP4 and FABP6 expression have no significant correlation in tumor size, tumor site, distant organ and lymph node metastasis, histologic grade, lymphatic permeation, neurological invasion, vascular invasion, and Duke’s and TNM classification. Multivariate logistic regression analysis showed that FABP4 and FABP6 were independent risk factors for CRC (adjusted odds ratio 1.916; 95%CI 1.340–2.492; P < 0.001; adjusted odds ratio 2.162; 95%CI 1.046, 1.078); P < 0.001, respectively). In discriminating CRC from the normal control, the optimal sensitivity of FABP4 and FABP6 were 93.20% (95%CI 87.8–96.7) and 83.70% (95%CI 76.7–89.3), respectively, while the optimal specificity of FABP4 and FABP6 were 48.8% (95%CI 39.8–57.9) and 58.4% (95%CI 49.2–67.1), respectively. When combined detection of serum carcinoembryonic (CEA) and FABP4 and FABP6, the optimal sensitivity and specificity were 61.33% (95%CI 53.0–69.2) and 79.82% (95%CI 71.3–86.8), respectively. Conclusion Increased expression of FABP4 and FABP6 not only were strong risk factors for the development of CRC but could also represent a potential biomarker for CRC diagnosis in Chinese patients. Combined detection of CEA with FABP4 and FABP6 could improve the diagnostic efficacy of CRC.

Expression of fatty acid binding protein 6 in bladder cancer and its clinical significance

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

The relationship between FAT10 mRNA expression and feature of clinical pathology in gastric carcinoma

High Expression of FABP4 and FABP6 in Patients with Colorectal Cancer.

Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers

Expression Profiles and Prognostic Value of FABPs in Colorectal Adenocarcinomas

The Predictive Value of PFKFB3 in Bladder Cancer Prognosis

FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer

Fatty Acid-Binding Protein 5 Predicts Poor Prognosis in Patients with Uveal Melanoma.

Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: a potential therapeutic target.

Expression of nucleosomal binding protein 1 in normal bladder mucosa and bladder cancer and its significance

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)

Expression of Survivin in Bladder Transitional Cell Carcinoma and Its Relationship with Expression of Fas/FasL

Expression of CUGBP1 and VEGF in Bladder Cancer and Their Clinical Significance

Fatty Acid Metabolism is Associated with Immune Microenvironment Variation in Bladder Cancer, and FN1 May Mediate PD-L1 Expression through the IL6-STAT3 Pathway

The Clinical Significance of B7-H4 Expression in Bladder Cancer

Expression of integrinα6β4 in bladder carcinoma and its implication

Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells

Expression of B7-H3 in muscle infiltrating bladder cancer and its clinical significance

Expression of urea transporter B in human bladder cancer tissue and its clinical significance

Decreased Expression of Liver-Type Fatty Acid-Binding Protein is Associated with Poor Prognosis in Hepatocellular Carcinoma.